17852-52-7

Basic information

• Product Name: 4-Hydrazinobenzene-1-sulfonamide hydrochloride
• Synonyms: 4-SPH;p-Sulfonamidophenylhydrazine;4-Hydrazinobenzene-1;4-Sulphamoylphenylhydrazine hydrochloride, 4-(Aminosulphonyl)phenylhydrazine hydrochloride;4-Hydrazinobenzene-1-sulfonaMide;4-(sulfaMoylphenyl)hydrazine Monohydrochloride;4-Hydrazine benzene sulfonaMide hydrochloride;4-AMinosulfonylphenylhydrazine HCl
• CAS NO: 17852-52-7
• Molecular Formula: C₆H₉N₃O₂S*ClH
• Molecular Weight: 223.68
• EINECS: 202-637-1
• Product Categories: Phenylhydrazine;Celecoxib;pharmaceutical;Aromatic Carboxylic Acids, Amides, Anilides, Anhydrides & Salts
• Mol File: 17852-52-7.mol

Chemical Properties

• Melting Point: 149-152 °C(lit.)
• Boiling Point: 434.7 °C at 760 mmHg
• Flash Point: 216.7 °C
• Appearance: white to light yellow crystal powder
• Density: 1.644[at 20℃]
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• Water Solubility: Soluble in water.
• Sensitive: Hygroscopic
• CAS DataBase Reference: 4-Hydrazinobenzene-1-sulfonamide hydrochloride(CAS DataBase Reference)
• NIST Chemistry Reference: 4-Hydrazinobenzene-1-sulfonamide hydrochloride(17852-52-7)
• EPA Substance Registry System: 4-Hydrazinobenzene-1-sulfonamide hydrochloride(17852-52-7)

Safety Data

• Hazard Codes: Xn,Xi
• Statements: 22-36/37/38
• Safety Statements: 36-24/25
• WGK Germany: 3
• RTECS: DA9380000
• Hazardous Substances Data: 17852-52-7(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
4-Hydrazinobenzene-1-sulfonamide hydrochloride is used as an intermediate in the synthesis of various pharmaceutical compounds. Its primary application is in the production of Celebrex, an anti-inflammatory drug used to treat conditions such as arthritis, ankylosing spondylitis, and acute pain.
As an intermediate, 4-Hydrazinobenzene-1-sulfonamide hydrochloride plays a crucial role in the development of new drugs and therapeutic agents. Its unique chemical structure allows for further modification and functionalization, making it a versatile building block in the synthesis of various pharmaceutical compounds.

Flammability and Explosibility

Nonflammable

InChI:InChI=1/C6H8N3O2S.ClH/c7-8-5-1-3-6(4-2-5)9-12(10)11;/h1-4,8H,7H2,(H,9,10,11);1H

Upstream product

• 35282-78-1 4-(aminosulphonyl)benzenediazonium chloride 
• 63-74-1 sulfanilamide 

Downstream Products

• 251443-35-3 1-(4-aminosulphonylphenyl)-4,5-dihydro-5-(3-methyl-4-methoxyphenyl)-3-trifluoromethyl-1H-pyrazole 
• 111607-53-5 4-{N'-[(E)-1-Phenyl-3-p-tolyl-prop-2-en-(E)-ylidene]-hydrazino}-benzenesulfonamide 
• 150981-69-4 4-{5-[2-(4-Chloro-phenyl)-2H-[1,2,3]triazol-4-yl]-3-phenyl-4,5-dihydro-pyrazol-1-yl}-benzenesulfonamide 
• 150981-74-1 4-{5-[2-(4-Bromo-phenyl)-2H-[1,2,3]triazol-4-yl]-3-phenyl-4,5-dihydro-pyrazol-1-yl}-benzenesulfonamide 
• 150981-78-5 4-{5-[2-(4-Bromo-phenyl)-2H-[1,2,3]triazol-4-yl]-3-p-tolyl-4,5-dihydro-pyrazol-1-yl}-benzenesulfonamide 
• 150981-72-9 4-{3-(4-Chloro-phenyl)-5-[2-(4-chloro-phenyl)-2H-[1,2,3]triazol-4-yl]-4,5-dihydro-pyrazol-1-yl}-benzenesulfonamide 
• 150981-77-4 4-{3-(4-Bromo-phenyl)-5-[2-(4-bromo-phenyl)-2H-[1,2,3]triazol-4-yl]-4,5-dihydro-pyrazol-1-yl}-benzenesulfonamide 
• 77121-23-4 4-(3-(4-chlorophenyl)-5-phenyl-4,5-dihydro-1H-pyrazol-1-yl)benzenesulfonamide 
• 122259-14-7 4-{N'-[(E)-1-(4-Methoxy-phenyl)-3-phenyl-prop-2-en-(E)-ylidene]-hydrazino}-benzenesulfonamide 
• 80883-92-7 4-(3-(4-methoxyphenyl)-5-phenyl-4,5-dihydro-1H-pyrazol-1-yl)benzenesulfonamide 
• 111607-56-8 4-{N'-[(E)-3-Phenyl-1-p-tolyl-prop-2-en-(E)-ylidene]-hydrazino}-benzenesulfonamide 
• 122259-16-9 4-{N'-[(E)-3-(4-Methoxy-phenyl)-1-phenyl-prop-2-en-(E)-ylidene]-hydrazino}-benzenesulfonamide 
• 71203-35-5 4-[4,5-dihydro-5-(4-methoxyphenyl)-3-phenyl-1H-pyrazol-1-yl]benzenesulfonamide 
• 6497-59-2 4-(3-Phenyl-3,3a,4,5-tetrahydro-benzo[g]indazol-2-yl)-benzenesulfonamide 

Relevant articles and documents

Anti-inflammatory Exploration of Sulfonamide Containing Diaryl Pyrazoles with Promising COX-2 Selectivity and Enhanced Gastric Safety Profile

Novel sulfonamide containing diaryl pyrazoles were synthesized and were subsequently tested for their in vitro cyclooxygenase inhibitory assay. Compounds that showed promising in vitro COX-2 IC50 values and selectivity indices were then evaluat

Design, synthesis and biological evaluation of some novel N-arylpyrazole derivatives bearing the sulfonamide moiety as cytotoxic agents

A series of novel N-arylpyrazole derivatives (4a–4l) bearing the sulfonamide moiety were synthesized by the condensation reaction of 1,3-dicarbonyl compounds with 4-hydrazinylbenzenesulfonamide. The structures of the obtained compounds were established on

Synthetic method of celecoxib intermediate P-hydrazinamide hydrochloride

The method, comprises the following steps :1): preparing a sulfanilamide hydrochloric acid aqueous solution, to prepare a sodium nitrite solution ;2) to acidify, and then acidifying the resulting reaction solution to 1 with ;3) powder, activated carbon to

HFO-1234yf as a CF3-Building Block: Synthesis and Chemistry of CF3-Ynones

Reaction of low cost, readily available 4th generation refrigerant gas 2,3,3,3-tetrafluoropropene (HFO-1234yf) with lithium diisopropylamide (LDA) leads to formation of lithium 3,3,3-trifluoropropynide, addition of which to a range of aldehydes formed CF3-alkynyl alcohol derivatives on multigram scale, which were oxidised using Dess–Martin periodinane (DMP) to give substituted CF3-ynones with minimal purification required. Michael-type additions of alcohol and amine nucleophiles to CF3-ynones are rapid and selective, affording a range of CF3-enone ethers and enaminones in excellent yields with high stereoselectivity for the Z-isomer. By analogous reactions with difunctional nucleophiles, a wide range of CF3-substituted pharmaceutically relevant heterocyclic structures can be accessed, exemplified in the simple synthesis of the anti-arthritis drug celecoxib from HFO-1234yf in just three steps.

Pyrazole–coumarin and pyrazole–quinoline chalcones as potential antitubercular agents

Pyrazole, coumarin, and quinoline are medicinally important moieties. In this study, two series of novel pyrazole–coumarin chalcones and pyrazole–quinoline chalcones were synthesized using multiple-step reactions. All the synthesized compounds were well c

CONTINUOUS PROCESSES FOR THE MANUFACTURE OF CELOCOXIB

A continuous process for the manufacture of celecoxib includes reacting a stream of a first solution of 4'-methylacetophenone in a first organic solvent and a stream of a second solution of ethyl trifluoroacetate in a second organic solvent in a first reactor in the presence of a base at a first reaction temperature of between 45°C and 90°C and at a first reaction pressure to form 4,4,4-Trifluoro-1-(4-methylphenyl)butane-1,3-dione. The first reaction pressure prevents boiling inside the first reactor. A stream of a first reactor product from the first reactor is continuously withdrawn, the first reactor product including a solution of 4,4,4-Trifluoro-1-(4-methylphenyl)butane-1,3-dione in the first organic solvent and the second organic solvent. A stream of the first reactor product and a stream of a third solution of (4-Sulfamoylphenyl)hydrazine hydrochloride in a third organic solvent are reacted in a second reactor at a second reaction temperature of between 80°C and 110°C and at a second reaction ressure to form celecoxib. The second reaction pressure prevents boiling inside the second reactor. A stream of a second reactor product is continuously withdrawn from the second reactor, the second reactor product including a solution of celecoxib in organic solvent.

An Integrated Continuous Flow Micro-Total Ultrafast Process System (μ-TUFPS) for the Synthesis of Celecoxib and Other Cyclooxygenase Inhibitors

Integrated continuous manufacturing has emerged as a promising device for the rapid manufacturing of active pharmaceutical ingredients (APIs). We herein report a newly designed continuous flow micro-total process system platform for the rapid manufacturing of celecoxib, a selective nonsteroidal anti-inflammatory drug. This approach has been proven generally for the synthesis of several alkyl and aryl substituted pyrazoles. In order to minimize the tedious work-up process of potential reaction intermediates/products, we have developed a continuous flow extraction and separation platform to carry out the entire reaction sequence resulting in a short residence time with good yield. The present process was further extended to gram-scale synthesis of the COX-2-related API, viz. celecoxib, in the continuous flow process.

Novel (pyrazolyl)benzenesulfonamides with a nitric oxide-releasing moiety as selective cyclooxygenase-2 inhibitors

Abstract Inhibition of cyclooxygenase-2 (COX-2) is a promising anti-inflammatory therapeutic strategy, but long-term medication with COX-2-inhibitors (coxibs) may be associated with adverse cardiovascular effects. Functionalization of existing lead struct

Synthesis of tri- and tetrasubstituted pyrazoles via Ru(II) catalysis: Intramolecular aerobic oxidative C-N coupling

An unprecedented ruthenium(II)-catalyzed intramolecular oxidative C-N coupling method has been developed for the facile synthesis of a variety of synthetically challenging tri- and tetrasubstituted pyrazoles. Dioxygen gas is employed as the oxidant in this transformation. The reaction demonstrates excellent reactivity, functional group tolerance, and high yields.

Efficient sequential synthesis of PET Probes of the COX-2 inhibitor [ 11C]celecoxib and its major metabolite [11C]SC-62807 and in vivo PET evaluation

Synthesis of [11C]celecoxib, a selective COX-2 inhibitor, and [11C]SC-62807, a major metabolite of celecoxib, were achieved and the potential of these PET probes for assessing the function of drug transporter in biliary excretion was